Benchmark analyst Bill Sutherland lowered the firm’s price target on Quipt Home Medical (QIPT) to $4 from $6 and keeps a Buy rating on the shares after revenue missed expectations in fiscal Q2. On a positive note, Quipt continues to see no negative impact from GLP-1 medications on demand for sleep therapy set ups and supplies, like other respiratory-focused home medical equipment companies, the analyst noted.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QIPT:
- Quipt Home Medical: Resilience and Growth Potential Amidst Challenges
- Quipt Home Medical downgraded to Hold from Buy at Canaccord (yesterday)
- Quipt Home Medical downgraded to Hold from Buy at Canaccord
- Quipt Home Medical: Strategic Initiatives and Financial Resilience Amidst Revenue Challenges
- Quipt Home Medical Reports Q2 2025 Results Amid Revenue Challenges